Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO – Get Free Report)’s stock price passed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $0.21 and traded as low as $0.19. Northwest Biotherapeutics shares last traded at $0.1918, with a volume of 2,283,691 shares.
Northwest Biotherapeutics Stock Down 0.5%
The firm has a 50 day moving average price of $0.21 and a 200 day moving average price of $0.23. The stock has a market cap of $316.83 million, a PE ratio of -0.01 and a beta of -0.67.
Northwest Biotherapeutics Company Profile
Northwest Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of personalized dendritic cell immunotherapies for the treatment of cancer. The company’s proprietary platform harnesses patient-derived dendritic cells to present tumor-specific antigens and stimulate a targeted immune response. By tailoring each vaccine to the individual patient’s tumor profile, the approach aims to improve outcomes and reduce off-target toxicity associated with conventional therapies.
The company’s lead candidate, DCVax®-L, is designed for patients with newly diagnosed or recurrent glioblastoma multiforme (GBM) and has advanced through a global Phase III clinical trial.
See Also
- Five stocks we like better than Northwest Biotherapeutics
- Why KB Home Could Reward Patient Investors Later
- Meta’s Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time
- Tesla’s New NHTSA Probe Lands at the Worst Possible Time
- Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus
Receive News & Ratings for Northwest Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Northwest Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
